The Goldman Sachs Group Lowers Abbott Laboratories (NYSE:ABT) Price Target to $113.00

Key Points

• Goldman Sachs lowered its price target on Abbott Laboratories from $121 to $113, while keeping a buy rating on the stock.
• Other Wall Street firms also trimmed their targets or ratings recently, and the broader analyst consensus remains Moderate Buy with an average price target of $119.09.
• Abbott reported better-than-expected quarterly results, including $1.15 EPS and $11.16 billion in revenue, though the stock was down about 0.7% and traded near $86.05.

Abbott Laboratories (NYSE:ABT - Get Free Report) had its target price reduced by equities researchers at The Goldman Sachs Group from $121.00 to $113.00 in a report issued on Wednesday,MarketScreener reports. The firm currently has a "buy" rating on the healthcare product maker's stock. The Goldman Sachs Group's target price indicates a potential upside of 31.31% from the stock's current price.

Several other brokerages also recently issued reports on ABT. Mizuho cut their target price on shares of Abbott Laboratories from $125.00 to $115.00 and set a "neutral" rating on the stock in a research note on Friday, April 17th. Wells Fargo & Company reduced their price target on shares of Abbott Laboratories from $122.00 to $109.00 and set an "overweight" rating for the company in a research report on Friday, April 17th. Weiss Ratings downgraded shares of Abbott Laboratories from a "hold (c)" rating to a "hold (c-)" rating in a research report on Friday, April 24th. Citigroup cut their price target on Abbott Laboratories from $136.00 to $108.00 and set a "buy" rating for the company in a research note on Friday, April 17th. Finally, Daiwa Securities Group downgraded shares of Abbott Laboratories from an "outperform" rating to a "neutral" rating and set a $92.00 price target on the stock. in a report on Wednesday, April 22nd. Two research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $119.09.

Abbott Laboratories Stock Down 0.7%

ABT stock opened at $86.05 on Wednesday. The firm has a market cap of $149.89 billion, a PE ratio of 24.12, a P/E/G ratio of 1.46 and a beta of 0.65. Abbott Laboratories has a 12 month low of $81.97 and a 12 month high of $139.06. The firm has a 50 day simple moving average of $95.89 and a 200 day simple moving average of $111.43. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.39 and a quick ratio of 1.01.

Abbott Laboratories (NYSE:ABT - Get Free Report) last released its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, topping the consensus estimate of $1.14 by $0.01. The business had revenue of $11.16 billion during the quarter, compared to analyst estimates of $10.99 billion. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The company's revenue was up 7.8% compared to the same quarter last year. During the same period last year, the company posted $1.09 EPS. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Equities research analysts forecast that Abbott Laboratories will post 5.48 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, EVP Mary K. Moreland sold 613 shares of the firm's stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $70,850.54. Following the completion of the transaction, the executive vice president owned 104,291 shares of the company's stock, valued at approximately $12,053,953.78. This trade represents a 0.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP John A. Jr. Mccoy sold 585 shares of the business's stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $67,614.30. Following the sale, the vice president directly owned 24,628 shares in the company, valued at $2,846,504.24. This trade represents a 2.32% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 3,055 shares of company stock valued at $353,097. Corporate insiders own 0.46% of the company's stock.

Institutional Trading of Abbott Laboratories

Several hedge funds and other institutional investors have recently modified their holdings of the stock. MidAtlantic Capital Management Inc. acquired a new stake in Abbott Laboratories during the 4th quarter worth approximately $25,000. Cornerstone Financial Management LLC acquired a new stake in shares of Abbott Laboratories in the fourth quarter valued at approximately $25,000. Purpose Unlimited Inc. acquired a new stake in Abbott Laboratories during the fourth quarter worth approximately $25,000. Portfolio Resources Advisor Group Inc. acquired a new position in Abbott Laboratories in the 4th quarter valued at $26,000. Finally, Abound Financial LLC bought a new stake in shares of Abbott Laboratories during the 4th quarter valued at $26,000. Institutional investors own 75.18% of the company's stock.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.